BI
BIAFW
bioAffinity Technologies, Inc.
$0.2950
0.00%
$899.3K
No data for this timeframe.
Vol
Market Cap$899.3K
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$15.7K
Inst. Activity1 buys / 1 sells
SEC Reports7
Exchange Nasdaq·Sector Services-Commercial Physical & Biological Research·Inc. DE·CIK 0001712762·Prev Close $0.2950
Recent Activity
Jun 2, 2026
SEC
bioAffinity Technologies announced via an 8-K that the Society for Advanced Bronchoscopy will host a webinar on June 16,
8-K — Impact 2/10
May 27, 2026
SEC
bioAffinity Technologies announced it received a notification of allowance from the Mexican Institute of Industrial Prop
8-K — Impact 4/10
May 13, 2026
SEC
The SEC declared effective the resale registration statement (S-1, File No. 333-295465) for bioAffinity Technologies, In
EFFECT — Impact 3/10
Inst.
UBS Group AG — DOUBLED
48,283 shares ($9.2K)
Inst.
CITADEL ADVISORS LLC — TRIM
35,988 shares ($6.8K)
Latest Reports
NEUTRAL
8-K
2/10
bioAffinity Technologies announced via an 8-K that the Society for Advanced Bronchoscopy will host a webinar on June 16,
Jun 2, 2026
NEUTRAL
8-K
4/10
bioAffinity Technologies announced it received a notification of allowance from the Mexican Institute of Industrial Prop
May 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $15.7K | DOUBLED |
1 institutional holders with $15.7K total value (47,669 shares) as of 2025-Q3. Top holders: UBS.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 47,669 | $15.7K | 100.0% | DOUBLED +7160.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | DOUBLED | 665 | 48,283 | +7160.6% | $9.2K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 50,245 | 35,988 | -28.4% | $6.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 39,180 | 50,245 | +28.2% | $17.1K | 2024-Q4 |
| UBS Group AG | ADD | 467 | 665 | +42.4% | $199.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 6 neutral. Avg impact: 3.4/10.
NEUTRAL
8-K
2/10
bioAffinity Technologies announced via an 8-K that the Society for Advanced Bronchoscopy will host a
Jun 2, 2026
NEUTRAL
8-K
4/10
bioAffinity Technologies announced it received a notification of allowance from the Mexican Institut
May 27, 2026
NEUTRAL
EFFECT
3/10
The SEC declared effective the resale registration statement (S-1, File No. 333-295465) for bioAffin
May 13, 2026
NEUTRAL
8-K
4/10
bioAffinity Technologies announced via an 8-K that unit sales of its CyPath Lung diagnostic test rea
May 12, 2026
MIXED
8-K
5/10
bioAffinity Technologies reported Q1 2026 revenue of $1.4M, down 27% YoY from $1.9M due to the disco
May 8, 2026
NEUTRAL
8-K
3/10
bioAffinity Technologies announced a new clinical case study demonstrating the use of its CyPath Lun
Apr 14, 2026
NEUTRAL
8-K
3/10
bioAffinity Technologies announced that its CyPath® Lung test will be featured at the Cleveland Clin
Apr 7, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.